Zymeworks Inc. (ZYME) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Kenneth H. Galbraith	Chairman of the Board, Chief Executive Officer & President	1.71M	1962
Paul Moore	Chief Scientific Officer	998,368	1968
Mark Hollywood	Executive VP & Chief Operating Officer	0	1969
Sabeen Mekan	SVP & Chief Medical Officer	0	1980
Lindsey Foulkes	SVP of Corporate Development & Strategy	0	N/A
Paul R. Schneider	Executive VP & General Counsel	0	1971
Laura O'Connor	Senior VP & Chief Human Resources Officer	0	N/A
Shrinal Inamdar	VP of Investor Relations	0	N/A
Scott Platshon	Executive VP & Chief Business Officer	0	1991
Diana Papove	Vice President of Corporate Communications	0	N/A
Kristin Stafford	Executive VP & CFO	0	1982
Bijal Desai	Senior Vice President of Finance	0	N/A

Name

Title

Pay

Year Born

Kenneth H. Galbraith

Chairman of the Board, Chief Executive Officer & President

1.71M

1962

Paul Moore

Chief Scientific Officer

998,368

1968

Mark Hollywood

Executive VP & Chief Operating Officer

1969

Sabeen Mekan

SVP & Chief Medical Officer

1980

Lindsey Foulkes

SVP of Corporate Development & Strategy

N/A

Paul R. Schneider

Executive VP & General Counsel

1971

Laura O'Connor

Senior VP & Chief Human Resources Officer

N/A

Shrinal Inamdar

VP of Investor Relations

N/A

Scott Platshon

Executive VP & Chief Business Officer

1991

Diana Papove

Vice President of Corporate Communications

N/A

Kristin Stafford

Executive VP & CFO

1982

Bijal Desai

Senior Vice President of Finance

N/A

Description

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.